NCT02612623 - An 8-Week Refractory Chronic Cough Study (MK-7264-021) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2015

Primary Completion Date

May 4, 2016

Study Completion Date

May 18, 2016

Conditions

Refractory Chronic Cough

Interventions

DRUG

Gefapixant

Gefapixant tablets administered by mouth twice daily for 8 weeks

DRUG

Placebo (for gefapixant)

Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks

Trial Locations (10)

Afferent Investigative Site, Mission Viejo

Afferent Investigative Site, San Jose

Afferent Investigative Site, Colorado Springs

Afferent Investigative Site, Largo

Afferent Investigative Site, Charlotte

Afferent Investigative Site, Tulsa

Afferent Investigative Site, Dallas

Afferent Investigative Site, San Antonio

Afferent Investigative Site, Bellevue

Afferent Investigative Site, Greenfield

All Listed Sponsors

lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY